ebs-20241212

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2024

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 16, 2024, Emergent BioSolutions Inc. (“Emergent”) announced that it received a contract option modification (“Modification No. 18”) of the BARDA AV7909 Contract (as defined below) from from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued at $50 million. This modification relates to Emergent’s AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority, which became effective on September 30, 2016 (the “BARDA AV7909 Contract”) and has been modified from time to time.

The preceding description of Modification No. 18 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 18, filed as Exhibit 10.1 to this Current Report. The BARDA AV7909 Contract was filed as Exhibit 10.2 to Emergent’s Quarterly Report on Form 10-Q for the period ended September 30, 2016, which was filed with the U.S. Securities and Exchange Commission on November 9, 2016.

On January 8, 2025, the Company announced the exercise of a contract option and modification (“Modification No. 3”) to the indefinite-delivery, indefinite-quantity (IDIQ) procurement contract (the “BioThrax IDIQ Contract”) with the U.S. Department of Defense and led by The Joint Program Executive Office for Chemical, Biological Radiological and Nuclear Defense (JPEO-CBRND), valued at approximately $20 million to supply Emergent’s product BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.

The preceding description of Modification No. 3 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 3, filed as Exhibit 10.2 to this Current Report. The BioThrax IDIQ Contract was filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, which was filed on May 2, 2024.

On December 16, 2024, and January 8, 2025, Emergent issued press releases announcing the respective contract modifications as discussed above. Copies of the press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report and incorporated herein by reference

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description
10.1						Modification No. 18, effective December 12, 2024, to the BARDA AV7909 Contract.
10.2						Modification No. 3, effective December 13, 2024, to the BioThrax IDIQ Contract.
99.1						Press release issued by Emergent BioSolutions Inc. on December 16, 2024.
99.2						Press release issued by Emergent BioSolutions Inc. on January 8, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	EMERGENT BIOSOLUTIONS INC.

Dated: January 8, 2025	By:	/s/ Richard S. Lindahl
		Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

as an initial procurement to the Strategic National Stockpile {SNS). Emergent will be responsible for shipping and transport of filled and finished AV7909 product to the SNS and the costs associated with the delivery. Under CLIN 0006 Emergent shall manufacture, fill, and deliver [**] doses procured from [**] through [**], as an additional procurement to the SNS. Emergent will be responsible for shipping and transport of filled and finished AV7909 product to the SNS and the costs associated with the delivery. For CLINs 0004 and 00006, BARDS may accept “Short Dated Doses” (doses dated [**] months but [**] months from the date of manufacture if such doses are delivered along with the appropriate number of additional doses (“Additional Doses”). Additional Doses shall be calculated at [**]% of the number of delivered Short Dated Doses (e.g. [**] Short Dated Doses + [**] Additional Doses for a total delivery of [**] doses). For CLIN 0011A ed Shelf- [**] [**] from the date of manufacture) at a discounted price. These anthrax vaccine doses will have two different unit prices depending on the age of the vaccine post- manufacture. Vaccine doses delivered up to or equal to [**] months from their manufacture date will be charged a dose price of $[**] per dose. Vaccines delivered with a reduced shelf life [**] months, but [**] months post-manufacture will be charged a unit dose price of $[**] per dose. BARDA will not accept any vaccine older than [**] months post-manufacture. For CLIN 0011B, Emergent shall provide [**] doses, dated less than or equal to [**] months from the date of manufacture (> [**] month shelf life at month of delivery at $[**] per dose between [**] through [**]. For CLIN 0011C, Emergent shall provide [**] doses, dated less than or equal to [**] months from the date of manufacture (> [**] month shelf life at month of delivery) at $[**] per dose and [**] doses, dated less than or equal to [**] months from the date of manufacture (> [**] month shelf life at month of delivery). For CLIN 0011D, Emergent shall provide an estimated [**] doses, dated less than or equal to [**] months from the date of manufacture (> [**] month shelf life at month of delivery) at $[**] per dose and an estimated [**] doses, dated less than or equal to [**] months from the date of manufacture (> [**] month shelf life at month of delivery). For delivery to the SNS, Emergent shall comply with the relevant associated activities and deliverables as outlined in the Quality Agreement {attached) as signed by Emergent, BARDA, and the SNS. Emergent shall provide appropriate documentation to BARDA for quality assurance of the final drug product delivered to the SNS and invoice appropriately. 1.9 Reporting Requirements and Deliverables Reports As part of the work to be performed under this contract, Emergent will prepare and deliver the following reports throughout the period of performance. Monthly Technical Progress Reports On the fifteenth {15) day of each month for the previous calendar month, Emergent will submit to the COR and the CO a Technical Progress Report covering the previous calendar month. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period will consist of each calendar month. The frequency of Technical Progress Reporting will be determined by the CO and COR during negotiations of the contract. The format and type of Technical Progress Report and Executive Summary will be provided by the COR. The Technical Progress Reports will summarize progress for the reporting period, such as: management and administrative updates, December 2024 Page 7

SEE SCHEDULE AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. 15A. NAME AND TITLE OF SIGNER (Type or print) 30-105-04EXCEPTION TO SF 30 APPROVED BY OIRM 11-84 STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243 The purpose of this modification to exercise Option CLIN 1001. 1. CONTRACT ID CODE PAGE OF PAGES 1 4 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) 16C. DATE SIGNED BY 16B. UNITED STATES OF AMERICA15C. DATE SIGNED15B. CONTRACTOR/OFFEROR (Signature of Contracting Officer)(Signature of person authorized to sign) 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 9B. DATED (SEE ITEM 11) X W911SR24F0016 10B. DATED (SEE ITEM 13) X 9A. AMENDMENT OF SOLICITATION NO. 22-Jan-2024 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer is extended, is not extended. Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 12. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. X IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR 52.217-9 Option to Extend the Terms of the Contract D. OTHER (Specify type of modification and authority) E. IMPORTANT: Contractor is not, X is required to sign this document and return 1 copies to the issuing office. 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) 10A. MOD. OF CONTRACT/ORDER NO. 2. AMENDMENT/MODIFICATION NO. 5. PROJECT NO.(If applicable) 6. ISSUED BY 3. EFFECTIVE DATE 13-Dec-2024 CODE USA CONTRACTING CMD-APG. - W911SR EDGEWOOD CONTRACTING DIVISION 8456 BRIGADE STREET BLDG E4215 ABERDEEN PROVING GROUND MD 21010-5401 W911SR 7. ADMINISTERED BY (If other than item 6) 4. REQUISITION/PURCHASE REQ. NO. CODE See Item 6 EMERGENT BIODEFENSE OPERATIONS LANSING L EMERGENT BIODEFENSE 3500 N MARTIN LUTHER KING JR BLVD LANSING MI 48906-2933 FACILITY CODE1H0B6CODE EMAIL:TEL: Modification Control Number: mjohn1sr2514 MAZEN.BRIAN.E.1387647780 Digitally signed by MAZEN.BRIAN.E.1387647780 Date: 2024.12.11 12:47:22 -05'00' Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.

W911SR24D0001 W911SR24F0016 (mjohn1sr2514) Page 2 of 4 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES SECTION SF 30 - BLOCK 14 CONTINUATION PAGE The following have been added by full text: P00003 The purpose of this modification is as follows: 1. To exercise Option CLIN 1001. 2. To provide incremental funding for Option CLIN 1001 in the amount of $[**] to procure [**] doses of BioThrax® AVA (Anthrax Vaccine Absorbed). 3. Pursuant to DFARS 252.232-7007, Limitation of Government’s Obligation, initial funding in the amount of $[**] is hereby added to Contract Line Item Number (CLIN) 1001 as shown in the table below. CLIN CLIN Amount Current Funding Total Funding Balance to be funded 1001 $[**] $[**] $[**] $[**] 4. Except as provided herein, all terms and conditions remain unchanged. SECTION SF 1449 - CONTINUATION SHEET SOLICITATION/CONTRACT FORM The total cost of this contract was increased by $[**] from $[**] to $[**]. SUPPLIES OR SERVICES AND PRICES CLIN 1001 The option status has changed from Option to Option Exercised. SUBCLIN 100101 is added as follows:

W911SR24D0001 W911SR24F0016 (mjohn1sr2514) Page 3 of 4 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 100101 $0.00 Funding FFP Funding in support of CLIN 1001. PURCHASE REQUEST NUMBER: 0012227877 NET AMT $0.00 ACRN AC CIN: GFEBS001222787700001 $[**] ACCOUNTING AND APPROPRIATION Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $[**] from $[**] to $[**]. SUBCLIN 100101: Funding on SUBCLIN 100101 is initiated as follows: 0012510.9.2.5.7 6100.9000021001 ACRN: AC CIN: GFEBS001222787700001 Acctng Data: 0212024202520400000665654255 A. Increase: $[**] Total: $[**] Cost Code: A5XAH DELIVERIES AND PERFORMANCE The following Delivery Schedule item for CLIN 1001 has been changed from: DELIVERY DATE QUANTITY SHIP TO ADDRESS DODAAC / CAGE 31-JUL-2025 [**] MURTECH, INC MANN 820 CROMWELL PARK DR, STE J GLEN BURNIE MD 21061-2574 FOB: Origin (Shipping Point) W56XNH

W911SR24D0001 W911SR24F0016 (mjohn1sr2514) Page 4 of 4 To: DELIVERY DATE QUANTITY SHIP TO ADDRESS DODAAC / CAGE 25-SEP-2025 [**] MURTECH, INC MANN 820 CROMWELL PARK DR, STE J GLEN BURNIE MD 21061-2574 FOB: Origin (Shipping Point) W56XNH INSPECTION AND ACCEPTANCE The following Acceptance/Inspection Schedule was added for SUBCLIN 100101: INSPECT AT INSPECT BY ACCEPT AT ACCEPT BY N/A N/A N/A N/A (End of Summary of Changes)

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).

Deliveries are expected to begin this calendar year and be complete by April 2025. This award follows a previously announced contract modification of $30.0 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) this year.

CYFENDUS® vaccine was approved by the U.S. Food & Drug Administration (FDA) in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age. Anthrax is a Tier 1 biological select agent due to its potential to be used for a bioterrorist incident and threat to public health and national security.

“An anthrax emergency continues to be a significant public health threat due to its ability to be easily disseminated, lethality, and potential for widespread impact,” said Paul Williams, senior vice president, products head at Emergent. “This procurement award further bolsters anthrax preparedness and demonstrates Emergent’s commitment to public health preparedness.”

In addition to the CYFENDUS® vaccine, Emergent’s anthrax franchise includes the BioThrax® vaccine, which continues to serve a critical purpose, as well as two treatments, Anthrasil® [Anthrax Immune Globulin Intravenous (Human)], a polyclonal antibody therapeutic, and raxibacumab, a monoclonal antibody therapeutic.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract HHSO100201600030C.

About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Indication

CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs.

The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.

Important Safety Information

Contraindication: Do not take CYFENDUS® vaccine if you are allergic to CYFENDUS® vaccine, BioThrax® (Anthrax Vaccine Adsorbed) or any ingredient of the vaccine.

Allergic reactions: Appropriate medical treatment and supervision must be available after receiving CYFENDUS® vaccine to manage possible serious allergic reactions. Get medical help right away if you have any symptoms of a serious allergic reaction.

Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to CYFENDUS® vaccine.

Pregnancy: CYFENDUS® vaccine can cause fetal harm when administered to a pregnant individual. Before getting CYFENDUS® vaccine, tell your healthcare provider if you may be pregnant, plan to get pregnant soon, or are nursing a baby.

Adverse reactions: The most common adverse reactions reported were tenderness, pain, warmth, itching, swelling, redness, bruising, arm motion limitations, muscle aches, tiredness, headache, and fever.

U.S. Prescribing Information

The full Prescribing Information for CYFENDUS® vaccine can be found here.

About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of CYFENDUS® vaccine and the continued development of Emergent’s anthrax franchise, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

[email protected]

Media Contact:

Assal Hellmer

Vice President, Communications

[email protected]

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

GAITHERSBURG, Md., Jan. 8, 2024 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025.

“We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax® to protect our nation’s service members who have a high risk of exposure to anthrax,” said Paul Williams, senior vice president, products head at Emergent. “This procurement ensures a continued supply of this important medical countermeasure to the U.S. military and demonstrates our commitment to delivering solutions that address our customers’ needs to prepare for public health threats.”

This option is under Emergent’s existing indefinite-delivery, indefinite-quantity (IDIQ) procurement contract (W911SR24D0001) with the DoD and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to supply BioThrax® for use by all branches of the U.S. military as pre-exposure prophylaxis (PrEP) for anthrax disease.

On December 16, 2024, Emergent announced a $50 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) to procure doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). In addition to BioThrax® and CYFENDUS®, Emergent’s anthrax franchise includes two treatments, Anthrasil® [Anthrax Immune Globulin Intravenous (Human)], a polyclonal antibody therapeutic, and raxibacumab, a monoclonal antibody therapeutic.

About BioThrax® (Anthrax Vaccine Adsorbed)

Indication

BioThrax® (Anthrax Vaccine Adsorbed) is a vaccine indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age.

BioThrax® is approved for: (1) Pre-exposure prophylaxis of disease in persons at high risk of exposure. (2) Post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.

The efficacy of BioThrax® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.

Important Safety Information

Contraindications: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax® or a component of the vaccine.

Latex: The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals.

Pregnancy: Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus.

History of Anthrax Disease: History of anthrax disease may increase the potential for severe local adverse reactions.

Altered Immunocompetence: If BioThrax® is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Limitations of Vaccine Effectiveness: Vaccination with BioThrax® may not protect all individuals.

Adverse reactions: The most common (>10%) local (injection-site) adverse reactions observed in

clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache.

U.S. Prescribing Information

The full Prescribing Information for BioThrax® vaccine can be found here.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, supply and government procurement of BioThrax® vaccine and the continued development of Emergent’s anthrax franchise, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

[email protected]

Media Contact:

Assal Hellmer

Vice President, Communications

[email protected]